MedTrace Logo

Allogeneic Adoptive Immune Therapy for Advanced AIDS Patients

NCT04098770 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2024-01-05

No results posted yet for this study

Summary

Combined antiretroviral therapy (ART) efficiently suppresses viral replication and markedly decreases mortality among patients with HIV-1 infection/AIDS. While the advanced AIDS patients with CD4+T cell count less than 200 cells/µL often develop seriously opportunistic infections (OIs), severe wasting syndrome, and other fatal complications, which are the major causes of death in these patients. There has been no effective immune therapy for advanced AIDS patients who had a high mortality rate even in the era of cART. This clinical trail is to inspect the efficiency of allogeneic adoptive immune therapy for advanced AIDS patients.

Conditions

  • AIDS Patients

Interventions

BIOLOGICAL

Allogeneic Adoptive Immune Therapy

A dose (2-3 times) of AAIT was added on conventional treatment for advanced AIDS patients

Sponsors & Collaborators

  • The 6th people's Hospital of Xinjiang province

    collaborator UNKNOWN

  • The 4th people's hospital of Nanning City

    collaborator UNKNOWN

  • The 3th people's hospital of Shenzhen City

    collaborator UNKNOWN

  • Shanghai Public Health Clinical Center

    collaborator OTHER_GOV

  • Yunnan Provincial Hospital of Infectious Diseases

    collaborator UNKNOWN

  • Beijing 302 Hospital

    lead OTHER

Principal Investigators

  • Fu-Sheng Wang, MD · Beijing 302 Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-11
Primary Completion
2023-12-30
Completion
2024-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04098770 on ClinicalTrials.gov